entertainment -WSS

entertainment

author：fashion 2025-08-26 23:44:01 - browse：88785

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Merck drug for rare lung condition set for approval in U.S.

knowledge

WSS

Washington mulls new rules to avert another Change Healthcare

Obesity now affects over 1 billion people worldwide, study finds

Biotech companies concerned about China biosecurity crackdown

Study says nonprofit hospitals fall short in charity care spending

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

In search for therapies for solid tumors, companies turn to claudin

entertainment

entertainment

focus

What does generative AI mean for health care? We asked experts

Congress gives doctors Medicare pay bump

Bright Health sells Medicare Advantage business to Molina

Abortion pill Supreme Court ruling could impact entire drug industry

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Cancer drug shortages should be causing more outrage

How to fix the rural physician shortage in the U.S.

Walensky prepares to leave CDC — and Congress — behind

RaDonda Vaught to speak at CommonSpirit event on patient safety

Wikipedia

Food as medicine: Medically tailored meals may get standardized

Why the world’s most expensive drug might be worth the price

Readout Newsletter: Merck, Vertex, and Viking updates

How to fix the rural physician shortage in the U.S.

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

FDA does about

knowledge

focus

hotspot

focus